Afro-Egypt J Infect  Endem  Dis  2017 September ; 7(3):155

Efficacy of Sofosbuvir Plus Ribavirin with and without Pegylated Interferon in Management of Egyptian Chronic Hepatitis C Patients

Magdy Al Dahshan1, Samy Zaky2, Sameh Mohamed Seif El-Din3, Mohammed Salah Ali1, Alaa Nouh4 , Radi Hammad3

1Internal Medicine Department, Al-Azhar University, Cairo, Egypt

2Tropical Medicine Department, Al-Azhar University, Damita, Egypt

3Internal Medicine Department, National Hepatology and Tropical Medicine Research Institute,                                       Cairo, Egypt

4Tropical Medicine Department, Menoufia University, Menoufia, Egypt



Background and study aim: Egypt is one of the highest prevalence of antibodies to hepatitis C virus (HCV) in the world, estimated nationally at 6.3%. Applying best treatment protocol has a great impact on the national disease burden. DAAs open the door to decrease HCV prevalence as well as to treat infected subjects.

Patients and Methods: In this study 1000 patients treated by Pegylated interferon, Sofosbuvir and weight adjusted Ribavirin. Another group of 1000 patients treated by Sofosbuvir and weight adjusted Ribavirin.

Results: Two groups showed sustained virological response : 90.1% and 72.3% respectively. Both groups approved that previous treatment status and viral load has no impact on response prediction. Both showed that males are more likely to respond than females.

Conclusion: Addition of Direct Acting Antivirals (DAAs), like sofosbovir, to the standard treatment with interferon and ribavirin improved the duration of the treatment and the sustained virological response (SVR). Treating of cirrhotics by PEGINF+SOF+RBV and SOF+RBV leads to decrease success rates. Validation of SVR once will be a golden rule.